Literature DB >> 9731947

Intracellular accumulation, subcellular distribution and efflux of tilmicosin in swine phagocytes.

B Scorneaux1, T R Shryock.   

Abstract

Tilmicosin is a semi-synthetic macrolide antibiotic, currently approved for veterinary use in cattle and swine respiratory disease. As the concentrations of tilmicosin are generally low in swine lung tissue, the interaction of tilmicosin with three types of swine phagocytes (monocyte-macrophages, alveolar macrophages, and neutrophils) was evaluated to provide an understanding of clinical efficacy. After incubation with radiolabelled tilmicosin, uptake was determined and expressed as the ratio of the intracellular (Ci) to the extracellular (Ce) drug concentration (Ci/Ce). Tilmicosin was avidly accumulated by the swine phagocytes (Ci/Ce 48-69 at 4 h incubation) with 51 to 85% localized in the lysosomes. Uptake was dependent on cell viability, temperature and pH, but was not influenced by the metabolic inhibitors, sodium cyanide or potassium fluoride. However, lipopolysaccharide (LPS) exposure increased tilmicosin uptake by the swine phagocytes. In neutrophils, upon removal of extracellular tilmicosin, 60% of the intracellular tilmicosin was effluxed within the first 30 min, but after 4 h of incubation in drug-free medium, 25% remained cell-associated. In contrast, after 4 h of incubation in drug-free medium, 60% and 45% of tilmicosin remained cell-associated, within alveolar macrophages and monocyte-derived macrophages, respectively. Tilmicosin uptake was observed to increase lysosomal enzyme (acid phosphatase, lysozyme and beta-glucuronidase) production. Finally, neutrophils were shown to transport and efflux bioactive tilmicosin in a test system measuring both neutrophil chemotaxis under agarose and a bioassay measuring inhibition of bacterial growth in the presence of antibiotic in agar. These in vitro interactions of tilmicosin with swine phagocytes suggest an integral role in effecting clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731947     DOI: 10.1046/j.1365-2885.1998.00133.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  4 in total

1.  Pharmacokinetics of tilmicosin (Provitil powder and Pulmotil liquid AC) oral formulations in chickens.

Authors:  E A Abu-Basha; N M Idkaidek; A F Al-Shunnaq
Journal:  Vet Res Commun       Date:  2007-05       Impact factor: 2.459

2.  Kinetics and intrapulmonary disposition of tilmicosin after single and repeated oral bolus administrations to rabbits.

Authors:  G Gallina; L Lucatello; I Drigo; M Cocchi; S Scandurra; F Agnoletti; C Montesissa
Journal:  Vet Res Commun       Date:  2010-06       Impact factor: 2.459

3.  Efficacy of tilmicosin in the control of experimentally induced Actinobacillus pleuropneumoniae infection in swine.

Authors:  Marie-Anne Paradis; Gordon H Vessie; John K Merrill; C Paul Dick; Camille Moore; George Charbonneau; M Gottschalk; Janet I MacInnes; Robert Higgins; K R Mittal; C Girard; Jeffery J Aramini; Jeffrey B Wilson
Journal:  Can J Vet Res       Date:  2004-01       Impact factor: 1.310

4.  Efficacy of enteric-coated tilmicosin granules in pigs artificially infected with Actinobacillus pleuropneumoniae serotype 2.

Authors:  Zhen Dong; Xu-Zheng Zhou; Ji-Chao Sun; Xiao-Bin Meng; Hong-Sheng Li; Fu-Sheng Cheng; Xiao-Juan Wei; Bing Li; Wei-Wei Wang; Ji-Yu Zhang
Journal:  Vet Med Sci       Date:  2019-10-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.